Bradley Campbell is president and chief executive officer of Amicus Therapeutics and is also a member of its Board of Directors. Mr. Campbell joined Amicus in 2006 and led the global organization responsible for the commercialization of Galafold®. He also oversaw the corporate development, technical operations, market access, program management, clinical operations, and regulatory affairs … Read more
Craig D. Gordon, M.D., is the founder of GordonMD Global, a private and public long-biased global biopharmaceutical investment firm. Prior to establishing his own firm, he was an Equity Investment Analyst at The Capital Group for over ten years with research and investment responsibilities for U.S. and Japanese biotechnology and pharmaceutical companies. Before joining Capital, he … Read more
Dr. Julie Hambleton is a biotechnology and pharmaceutical executive with over 20 years of experience leading oncology companies. Most recently she served as interim chief executive officer at Arch Oncology. Previously, she served as senior vice president, chief medical officer and head of development at IDEAYA Biosciences. Prior to her role at IDEAYA, she held … Read more
Gary Sender is a seasoned executive and board member with more than 25 years of financial leadership experience in organizations ranging from large, multi-national pharmaceutical firms to early-stage biotechnology companies. He was chief financial officer of Nabriva Therapeutics plc, a publicly traded biopharmaceutical company, from 2016 until March 2021 when he retired. Prior to Nabriva, … Read more
Dr. Peter Thompson is a member at OrbiMed Advisors LLC, an investment firm. Dr. Thompson currently serves on the boards of directors of Alpine Immune Sciences Inc., Corvus Pharmaceuticals, Inc., Decibel Therapeutics, Inc., Edgewise Therapeutics, Inc., Janux Therapeutics, Inc., and Silverback Therapeutics, Inc., as well as several private companies. Previously, Dr. Thompson served on the … Read more